Cargando…

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?

Detalles Bibliográficos
Autor principal:	Jeon, Chan Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean College of Rheumatology 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351408/ https://www.ncbi.nlm.nih.gov/pubmed/37476429 http://dx.doi.org/10.4078/jrd.22.0034

Ejemplares similares

Medical Students Who Do Not Match to Psychiatry: What Should They Do, and What Should We Do?
por: Balon, Richard, et al.
Publicado: (2020)

To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery?
por: van Duren, Bernard H, et al.
Publicado: (2021)

COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do?
por: Ikizler, T. Alp
Publicado: (2020)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

What Should We Do for Patients With Mitral Annular Calcification?
por: Cho, Dong-Hyuk
Publicado: (2022)

What should we do as orthopedic surgeons in catastrophic disasters?
por: Iwamoto, Yukihide
Publicado: (2012)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Rheumatoid arthritis: what do MRI and ultrasound show
por: Sudoł-Szopińska, Iwona, et al.
Publicado: (2017)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
por: Cho, Soo-Kyung, et al.
Publicado: (2017)

Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?
por: Romão, Vasco Crispim, et al.
Publicado: (2013)

What should we do to prevent and manage obesity in children and adolescents?
por: Yang, Hye Ran
Publicado: (2019)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Health of Refugees and Migrants—Where Do We Stand and What Directions Should We Take?
por: Keidar, Osnat, et al.
Publicado: (2019)

What Should We Eat?
Publicado: (1909)

Should We Use bDMARDs as an Induction Therapy in Early and Severe Rheumatoid Arthritis? Results at 5 years from the ERA UCLouvain Brussels Cohort
por: Sapart, Emilie, et al.
Publicado: (2023)

Heart Failure Awareness in the General Population: What Should We Do Next?
por: Kim, Myung-A
Publicado: (2020)

The COVID-19 pandemic and kangaroo mother care: What should we do?
por: Hakimi, Sevil
Publicado: (2020)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

What Pharmacometricians (Should) Do
por: van der Graaf, P H
Publicado: (2013)

Continuous cerebral blood flow monitoring: What should we do with these extra numbers?
por: Tupprasoot, Raksa, et al.
Publicado: (2023)

COVID-19 vaccine: what are we doing and what should we do?
por: Candelli, Marcello
Publicado: (2022)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Multinational monkeypox outbreak: what do we know and what should we do?
por: Memariani, Mojtaba, et al.
Publicado: (2022)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Keeping the Journal in the Second Quarter: What Are We Doing and What Will We Do?
por: Altay, Servet
Publicado: (2023)

Men's Health: What Should We Know?
por: Kim, Sae Woong
Publicado: (2015)

OA09 Challenging case of psoriatic arthritis: what should we do next?
por: Mohareb, Marwa, et al.
Publicado: (2022)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Rapidly organize redeployed medical staff in coronavirus disease 2019 pandemic: what we should do
por: Meng, Mei, et al.
Publicado: (2020)

Opportunities and challenges after biosecurity legislation — What we can and should do in environmental science and ecotechnology?
por: Wang, Aijie
Publicado: (2021)

What should we do about monkeypox?
por: Chen, Si, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2j222ph27db1mcrggs0uci943b